DMAC2

Across TCGA pan-cancer cohorts, DMAC2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of DMAC2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where DMAC2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DMAC2 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

LIHC, THCA, and HNSC are the cancer types where DMAC2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DMAC2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.991	<.001	9	view →
THCA	Male	IV	−0.423	<.001	9	view →
HNSC	All	II,III,IV	+0.280	<.001	9	view →
BRCA	All	III,IV	+0.385	<.001	6	view →
CHOL	Male	All	+1.753	<.001	5	view →
COAD	All	All	+0.301	.002	5	view →
KIRC	All	II,III,IV	−0.205	.018	4	view →
KICH	All	All	−0.387	.003	3	view →
LUAD	Female	II,III,IV	−0.279	.005	3	view →
ESCA	All	All	+0.566	.002	2	view →
LUSC	All	All	+0.164	.027	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

DMAC2–LIHC

Open the LIHC breakdown →